$TPST News

Tempest Therapeutics Q1 Adj. EPS $(0.50) Misses $(0.28) Estimate

Tempest Therapeutics To Present Most Recent Clinical Data From Lead Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy Product Candidate, TPST-2003, At ISCT Scientific Annual Meeting

Tempest Therapeutics Reaches Milestone In TPST-2003 Manufacturing Process

Tempest Therapeutics Q4 EPS $(0.62) Beats $(3.52) Estimate

Tempest Therapeutics Announces Up To $6M Private Placement; Warrants Will Have Exercise Price Of $2.16/Share

Tempest Therapeutics Selects Cincinnati Children's AGCTC As Lead Contract Development And Manufacturing Partner To Conduct Formal Technology Transfer Of TPST-2003 For Treatment Of rrMM

Tempest Therapeutics Announces Clinical Data From Ongoing REDEEM-1 Phase 1/2a Trial Evaluating TPST-2003, CD19/BCMA Dual-Targeting CAR-T Therapy

Tempest Therapeutics shares are trading higher after HC Wainwright & Co. upgraded the stock from Neutral to Buy rating and announced an $11 price target.

Tempest Therapeutics shares are trading higher after HC Wainwright & Co. upgraded the stock from Neutral to Buy rating and announced an $11 price target.

HC Wainwright & Co. Upgrades Tempest Therapeutics to Buy, Announces $11 Price Target

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Therapeutics shares are trading lower after the company announced a $4.25 million offering.

Tempest Therapeutics Announces ~$4.25M Offering Of 1.2M Common Stock, 1.2M Warrants At $3.625/Share

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast

Why Tempest Therapeutics (TPST) Stock Is Down 45% Today

Tempest shares are trading lower after the company announced it has signed agreements to acquire Factor Bioscience's Dual-CAR T programs in an all-stock transaction.

Tempest Announces Matt Angel To Assume Role Of President And CEO; Stephen Brady To Assume Role Of Chairman Of The Board Of Directors Upon Closing Of The Acquisition